SNAR-E: The Potential Drug Target and Biomarker (G100170220)

Target Name: SNAR-E

NCBI ID: G100170220

SNAR-E

Other Name(s): Small NF90 (ILF3) associated RNA E | small NF90 (ILF3) associated RNA E

SNAR-E: The Potential Drug Target and Biomarker

Sodium channels play a crucial role in many biological processes, including muscle contractions, nerve signals, and brain function. They are also involved in pain perception and other neurological disorders. The sodium channel drug target, also known as SNAR-E, has been identified as a potential drug target for treating various neurological disorders, including epilepsy, bipolar disorder, and migraine.

SNAR-E: Structure and Function

SNAR-E is a type of sodium channel that is expressed in the brain and other nervous cells. It is characterized by its unique structure, which consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's ability to interact with ligands, while the transmembrane domain is responsible for the protein's ability to conduct electrical signals. The intracellular domain is responsible for the protein's ability to modulate the activity of other sodium channels.

SNAR-E is involved in many important physiological processes in the brain, including the regulation of muscle contractions, the transmission of nerve signals, and the regulation of pain perception. It is also involved in the development and progression of several neurological disorders, including epilepsy, bipolar disorder, and migraine.

Drug Targeting

SNAR-E has been identified as a potential drug target for treating several neurological disorders. One of the main reasons for its potential as a drug target is its involvement in the regulation of pain perception. SNAR-E is known to play a role in the regulation of pain sensitivity and has been shown to contribute to the development of chronic pain disorders.

In addition to its role in pain perception, SNAR-E is also involved in the regulation of muscle contractions and the transmission of nerve signals. Its involvement in these processes makes it an attractive target for drugs that can modulate its activity and improve muscle and nerve function.

Biomarker

SNAR-E can also serve as a biomarker for several neurological disorders. Its involvement in the regulation of pain perception and its ability to modulate the activity of other sodium channels make it an potential target for drugs that can improve pain relief in individuals with neurological disorders.

Conclusion

SNAR-E is a potential drug target for treating several neurological disorders. Its unique structure and function, as well as its involvement in the regulation of pain perception and muscle contractions, make it an attractive target for drugs that can modulate its activity. Further research is needed to fully understand the potential of SNAR-E as a drug target and to develop effective treatments for neurological disorders.

Protein Name: Small NF90 (ILF3) Associated RNA E

The "SNAR-E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAR-E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets